Elicera Therapeutics plans first ELC-401 glioblastoma clinical trial after positive Swedish MPA feedback

• Elicera Therapeutics flagged plans for a first clinical study of CAR T candidate ELC-401 in glioblastoma; trial design is being finalized.
• No trial results were presented for ELC-401; regulatory feedback indicated the preclinical package supports starting clinical development.
• Separately, results were already presented from the CARMA study of ELC-301, showing broad tumor control with responses that appear durable.
• Funding from a rights issue, raising SEK 54.6 million before costs, is intended to support CARMA enrollment and accelerate ELC-401 readiness.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicera Therapeutics AB published the original content used to generate this news brief on August 28, 2026, and is solely responsible for the information contained therein.